source
- GSK drops camlipant cough drug after mixed Phase 3 resultsGSK announced it is halting development of camlipant, an experimental chronic cough medicine it acquired in a $2 billion purchase three years ago. The decision follows two Phase 3 trials that show…
- Mid-size biotech firms urge White House to scrap CMS GLOBE and GUARD pricing proposalsA group of midsized biotechnology companies met with officials from the White House and the Department of Health and Human Services this week. The companies presented a coordinated case to senior p…